Bank of Montreal Can increased its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 43.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 320,247 shares of the medical research company’s stock after buying an additional 96,368 shares during the period. Bank of Montreal Can owned 0.08% of Thermo Fisher Scientific worth $55,872,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in TMO. Confluence Investment Management LLC boosted its stake in Thermo Fisher Scientific by 4.0% in the second quarter. Confluence Investment Management LLC now owns 191,081 shares of the medical research company’s stock valued at $33,338,000 after buying an additional 7,324 shares in the last quarter. Fulton Bank N.A. acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $344,000. Private Trust Co. NA boosted its position in shares of Thermo Fisher Scientific by 11.0% in the second quarter. Private Trust Co. NA now owns 1,643 shares of the medical research company’s stock worth $286,000 after buying an additional 163 shares during the period. Iberiabank Corp boosted its position in shares of Thermo Fisher Scientific by 111.5% in the second quarter. Iberiabank Corp now owns 2,950 shares of the medical research company’s stock worth $515,000 after buying an additional 1,555 shares during the period. Finally, Caledonia Investments PLC boosted its position in shares of Thermo Fisher Scientific by 4.3% in the second quarter. Caledonia Investments PLC now owns 168,917 shares of the medical research company’s stock worth $29,471,000 after buying an additional 7,000 shares during the period. 83.52% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.61% during mid-day trading on Friday, reaching $186.00. 1,404,832 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $177.39 and its 200 day moving average price is $168.43. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $188.76. The stock has a market capitalization of $72.56 billion, a PE ratio of 32.40 and a beta of 1.04.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $2.03 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Shares Bought by Bank of Montreal Can” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/02/thermo-fisher-scientific-inc-tmo-shares-bought-by-bank-of-montreal-can.html.

A number of research analysts have weighed in on the stock. Cowen and Company reaffirmed a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Tuesday, August 1st. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. One research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $189.50.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,000 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now directly owns 38,757 shares in the company, valued at $6,790,226.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jim P. Manzi sold 11,318 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,344 shares of company stock valued at $3,741,071. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.